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Whole genome/exome sequencing (WGS/WES) has become widely adopted in
research and, more recently, in clinical settings. Many hope that the information obtained
from the interpretation of these data will have medical benefits for patients and—
in some cases—also their biological relatives. Because of the manifold possibilities
to reuse genomic data, enabling sequenced individuals to access their own raw
(uninterpreted) genomic data is a highly debated issue. This paper reports some of
the first empirical findings on personal genome access policies and practices. We
interviewed 39 respondents, working at 33 institutions in 21 countries across Europe.
These sequencing institutions generate massive amounts of WGS/WES data and
represent varying organisational structures and operational models. Taken together,
in total, these institutions have sequenced ∼317,259 genomes and exomes to date.
Most of the sequencing institutions reported that they are able to store raw genomic
data in compliance with various national regulations, although there was a lack of
standardisation of storage formats. Interviewees from 12 of the 33 institutions included in
our study reported that they had received requests for personal access to raw genomic
data from sequenced individuals. In the absence of policies on how to process such
requests, these were decided on an ad hoc basis; in the end, at least 28 requests
were granted, while there were no reports of requests being rejected. Given the rights,
interests, and liabilities at stake, it is essential that sequencing institutions adopt clear
policies and processes for raw genomic data retention and personal access.
Keywords: NGS, ELSI, policies, procedures, patient rights, research participant rights, raw, GDPR
INTRODUCTION
Whole genome sequencing (WGS) and whole exome sequencing (WES) have become widely
adopted in research and, more recently, in clinical practice (Birney et al., 2017; Birney, 2019). The
generated raw genomic data (i.e., WGS/WES data) include vast amounts of information of potential
importance to an individual’s current and future health, with implications for family members, if
analytic and interpretive hurdles can be overcome. The wide availability of genomic data also offers
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opportunities for reuse for additional clinical, health, research,
or recreational purposes. People requesting access to their own
raw data, however, raises a number of legal, ethical, and practical
questions. Legally, patients in many countries have a right to
access their health record (Thorogood et al., 2018). Individual
access rights are also being strengthened under data privacy
laws. For example, the European Union General Data Protection
Regulation (GDPR; European Parliament and Council, 2016), in
force since May 2018, stipulates a general right of data subjects
to access their personal data. GDPR leaves it to member states
to decide if and how this right applies in research contexts and
to raw genomic data specifically. Given the broad translational
spectrum in genomics, however, it can be difficult to clearly
distinguish clinical and research contexts (Schickhardt et al.,
2020). Another legal uncertainty is whether or not access rights
extend to raw sequence data, though broad definitions of
personal (health) data support this interpretation (Thorogood
et al., 2018). There are ethical arguments for and against
personal genome access.
On the one hand, some argue that research participants
and patients (collectively referred to as “sequenced individuals”)
have a moral right to access their own raw (uninterpreted)
genomic data in both clinical and research contexts as something
that fundamentally belongs to them (Nelson, 2016; Schickhardt
et al., 2020). Access can also potentially empower sequenced
individuals to direct the analysis and sharing of their own
data, potentially improving their own knowledge and health,
as well as accelerating research and innovation (Lunshof et al.,
2014; den Dunnen, 2015; Middleton et al., 2015; Wright et al.,
2017, 2019; Shabani et al., 2018; Thorogood et al., 2018).
Providing data may also be a way of encouraging and engaging
participants in research (Middleton et al., 2015). On the other
hand, some express concerns that providing personal access
is at best pointless and at worse harmful for individuals and
burdensome for providers and health systems (Bredenoord
et al., 2011). Individuals may not be able to do anything
with the genomic data, or they may misinterpret the data.
This is especially true if the data are of uncertain quality,
as is often the case in research contexts. They may share it
with unscrupulous researchers or unregulated service providers,
exposing them to further misinterpretations and privacy harms
(Guerrini et al., 2019). Of course, some of these risks can be
mitigated through clear policies, oversight, education, and access
to counseling services (Shabani et al., 2018; Schickhardt et al.,
2020). However, this, in turn, raises practical resource questions,
especially for research projects. Moreover, policies, processes, and
infrastructure are required to sustainably manage and transfer
large raw genomic data formats (Middleton et al., 2015; Wright
et al., 2017).
To better understand current practices of personal access
to raw genomic data by sequenced individuals, we conducted
interviews with genomics professionals working in institutions
within the EU/EEA that routinely perform WGS/WES
of human individuals on a large scale (i.e., “sequencing
institutions”). Sequencing institutions can be viewed as
gatekeepers or enablers for sequenced individuals in accessing
their personal raw genomic data. Furthermore, owing to
their geographical location and/or the data they use, these
institutions are expected to be directly impacted by the
GDPR, which makes their practices particularly insightful
and timely in light of the evolving regulatory landscape. For
uninitiated readers, the following primer describes the impact
of the GDPR on health research: Dove (2018). This study
is the first to provide empirical insights into the policies,
practices, and perspectives within sequencing institutions
pertaining to individual access to raw genomic data. We also
consider technical aspects of sequencing capacity and data
retention practices, as these variables determine the overall
availability of data. Our findings provide valuable empirical
observations that can inform legal and ethical debates over
personal genomic access, and indicate practical and technical
solutions for sequencing institutions seeking to respond
to such requests.
MATERIALS AND METHODS
Interview Guide
A semi-structured interview guide was prepared consisting of
questions pertaining to practices around WES/WGS, with a
particular focus on genomic data retention and provision of
access to sequenced individuals. The interview guide included
both closed-ended questions (aimed primarily at describing
the profile and practices of the sequencing centres) and open-
ended questions, intended to gauge respondents’ attitudes
toward a specific issue. To ensure a clear and intuitive
structure of interviews, we divided the interview guide into five
distinct sections (“modules”) addressing the following topics:
(i) organisational structure of the institution; (ii) sequencing
throughput and capacity; (iii) data management and storage
capacity; (iv) data retention policies and access policies for
sequenced individuals (to their own data); and (v) sequencing
centres’ experiences with receiving requests from individuals to
access their raw genomic data.
The draft versions of the interview guide underwent multiple
rounds of internal review and refinement. The final round of
refinement was carried out upon receiving feedback from the first
10 interviews within the study. The interview guide is available as
Supplementary File 1.
Identification of Sequencing Institutions
This interview study specifically targeted institutions located in
the EU/EEA that were member states of the EU/EEA, and that
generate, process, and/or manage human WGS/WES data for
research and/or clinical purposes. As such, we refer to such
institutions as “sequencing institutions.”
In order to identify sequencing institutions, we used all of the
following methods: (i) web searches, (ii) prior knowledge, (iii)
peer recommendations, (iv) media articles or announcements,
and (v) personal relationships. Our research strategy identified
83 sequencing institutions from 23 member states across
the EU/EEA region. Sequencing institutions were approached
individually with the request to participate in the study.
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Participant Recruitment
Recruitment of participants started in May 2018 and continued
in parallel to interviews with early respondents. A total of
64 sequencing institutions, out of a possible 83, were invited
to participate in the study via email, of which 33 eventually
agreed. Interviews took place between June 2018 and April 2019.
Individual respondents who participated in our study were all
affiliated with sequencing institutions, within which they held
various positions and responsibilities. Three interviews included
multiple respondents, with a maximum of five respondents from
the same institution being in the same interview. This brings the
total number of respondents to 39 (Supplementary File 2: Table
S1). Recruitment ended when it became clear from the interviews
that data saturation had been reached and no new insights were
emerging from additional interviews.
Pre-interview Communication
Respondents (representing sequencing institutions) who
agreed to take part in the interview study were provided
with information about the purpose of the interview, the
thematic areas of focus, and the methods (Supplementary
File 3). Potential respondents were also provided with a
confidentiality statement explaining how the collected data
would be treated (Supplementary File 4). Additional measures
for data privacy, confidentiality, and security are detailed within
Supplementary File 5.
Semi-Structured Interviews and
Recordings
Interviews were carried out either with Zoom video conferencing
software1 or in person. At the beginning of the interviews,
the interviewers briefly described the interview process and
addressed any issues of confidentiality and privacy of the
respondent (i.e., Supplementary Files 4, 5). The conversation
then proceeded with personal introductions by the interviewers
and respondents after which the interviews progressed according
to the interview guide (Supplementary File 1). At the end of the
interviews, the respondents were asked to provide concluding
remarks or suggestions, if any, for further improving the
interview guide.
Transcription and Review
Interviews were transcribed using otter.ai2, an automated,
artificial intelligence-based transcription software. The
automatically generated transcripts were reviewed for accuracy
and manually edited to correct any discrepancies with the
corresponding audio files. Reviewing and editing of transcripts
were carried out by VM/AB/SN and verified by RK for
validation purposes.
The process of transcription was combined with the
generation of interview summary documents called “review
sheets” (Supplementary File 6). For each review sheet, a set
of the most relevant quantitative and qualitative information,
1https://zoom.us/
2https://otter.ai/
deemed to best reflect the respondent’s views, were selected
from the corresponding interview transcript. The quotes were
accompanied by a concise written summary of the interview.
Subsequently, the review sheets were sent to the pertinent
respondents who had an opportunity to comment on the
document and suggest revisions if required.
Collection and Analysis of Informed
Consent Forms From Sequencing
Institutions
In addition to the data collected for the primary research (i.e.,
semi-structured interviews), samples of informed consent forms
that sequencing institutions use to consent sequenced individuals
were requested via email (from the respondent) or accessed
online, depending on their availability. We only collected
informed consent forms from the sequencing institutions
involved in the study.
Data Curation and Analyses
The process of data analysis was divided into two parts,
corresponding to the nature of the data being analysed
(quantitative and qualitative data analyses).
Quantitative Data Analysis and Visualisation
Quantitative data analysis was applied to questions requiring
numerical responses (e.g., no. of people sequenced), binary
answers (yes/no), or categorical variables (e.g., purchase year
of first Novaseq) from the interview transcripts that were
tabulated (Supplementary File 2: Tables S1–S6). The conversion
of the relevant information into the aforementioned format
was performed by AB and VM. The process was independently
repeated and refined by SN. Quantitative data analysis was
carried out using Google Sheets, as part of Google Suite, and R
statistical package (R Core Team, 2013). Data visualisation was
performed using ggplot2 graphical package (Wickham, 2016).
Diagrams, drawings, and schemes were generated using either
Google Slides (as part of Google Suite) or Adobe Illustrator. All
visualisations were refined using Adobe illustrator.
Qualitative Data Analysis
To analyse qualitative data collected through this study, we
employed deductive content analysis. In this approach, themes
or common content categories are pre-determined before data
analysis is undertaken, as opposed to being identified in the
course of data analysis (Graneheim and Lundman, 2004).
Qualitative data were organised under five broad themes, which
reflected the overall structure of the interview guide. The process
of organising the qualitative data under these themes was
undertaken by SN, AB, and VM and subsequently reviewed and
validated by RK.
Interview transcripts were carefully read to identify quotes
referring to one or more of the predetermined themes. The
relevant quotes were subsequently placed under the most suitable
theme. Quotes that bore relevance to more than one theme were
divided into multiple parts and the resultant sub-quotes were
placed under the suitable themes. Selection and categorisation of
the relevant quotes was performed by AB and VM. The process
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was independently validated by SN. Discrepancies in categorising
quotes were routinely discussed and resolved.
The analysis of the informed consent forms focused
exclusively on individual access to genomic data and genomic
data retention policies.
RESULTS
In total, the study included 33 interviews, conducted with 39
respondents within sequencing institutions, operating in 21
EU/EEA member states (Figure 1). They relate to more than
300,000 individuals, who underwent WGS/WES between the
early 1990s to the first half of 2019. We explored current
practices and policies of data management and personal raw
genomic data access for sequenced individuals within these
different institutions.
In line with our deductive content analysis approach, study
findings were organised into the following five sections: (i)
organisational structure and operational models; (ii) actual vs.
potential sequencing capacity; (iii) genomic data management
practices and policies; (iv) data access practices and policies; and
(v) future outlook.
Respondent Profiles, Organisational
Structure, and Operational Models
The first part of the interviews served as an introduction to
the respondent. Overall, the respondents held various positions
and responsibilities within those sequencing institutions,
including technical, academic, administrative, clinical, and
management (Figure 1).
Next, we sought to obtain a better understanding of the
organisational structure and the operations of sequencing
institutions, as those factors may influence processes and policies
for personal access to raw genomic data by sequenced individuals.
In terms of organisational structure, the study included mostly
(24,∼73%) public organisations, followed by six (∼18%) not-for-
profit private organisations, two (6%) commercial organisations,
and one consortium. Additionally, 19 (∼58%) of the participating
institutions performed sequencing for both research and clinical
purposes, while 11 (∼33%) and 3 (∼9%) institutions focused
exclusively on research or clinical sequencing, respectively
(Figure 1). The organisations included in this study varied
considerably in their size and number of personnel, with the
largest and the smallest institution housing approximately 3000
and 10 staff members, respectively (average∼450). Furthermore,
a total of∼460 personnel (average∼17, max.∼80, min. 3) within
those organisations were dedicated towards operating sequencing
platforms and data analyses and management (Supplementary
File 2: Table S2).
We then asked the respondents to elaborate on various
aspects of their operations, including (but not limited to) their
clientele, main activities (e.g., sequencing, or data processing),
their institutional arrangements (e.g., university hospital, private
laboratory), and whether they were outsourcing specific tasks or
processes, related to human genome sequencing.
We found that the sequencing institutions we covered
typically acted as service providers to healthcare and/or research
institutions, but delivered their services in different ways. In
this respect, we delineated four different “operational models”
to further classify the sequencing institutions as follows: (i)
dedicated, (ii) open, (iii) integrated, and (iv) outsourced.
Figure 1 provides an illustration and descriptions of the various
operational models and their adoption among sequencing
institutions included in our study. We found that most
sequencing institutions provided services to an exclusive set
of clients (i.e., dedicated), primarily made up of sequencing
laboratories affiliated with a specific clinical or research
institution, and performing sequencing services exclusively for
those affiliated institutions. Affiliations are determined either
through formal partnerships or based on geographical regions
(i.e., regional). Other institutions performed sequencing for any
internal or external clients as a standard service (i.e., open
model). There were also “integrated” sequencing institutions
that were physically located within the premises of a larger
organisation (e.g., a university, hospital, consortia/network).
Finally, there were 11 sequencing institutions that outsourced
their sequencing (i.e., outsourced model) and focused entirely on
data analysis and interpretation.
We found that 15 (45%) of the sequencing institutions
combined at least two operational models, with the most
prominent combination being the dedicated and integrated
models (i.e., 8, 24%). This implies that most of the integrated
sequencing institutions were dedicated to their “parent”
institution (e.g., hospital, university, consortium, network).
The second most frequent combination (i.e., 7, 21%) was the
coupling of the outsourced model with any of the other operation
models (Figure 1). Additionally, we identified two sequencing
institutions operating as data hubs that did not perform any
in-house sequencing, but aggregated and processed sequencing
data from multiple outsourced sequencing providers.
Actual vs. Potential Sequencing Capacity
We asked respondents about their institutions’ potential and
actual (i.e., throughput) sequencing capacities. The potential
sequencing capacity is defined as the theoretical maximum
amount of in-house sequencing (in gigabases) a given sequencing
institution can perform per annum, if they were to operate
at full capacity. These numbers were calculated on the basis
of publicly available information concerning the sequencing
platforms used by the participating institutions (Supplementary
File 2: Table S3). However, we lowered the estimates to 70% of
the maximum annual capacity in order to derive more realistic
assumptions, as a respondent duly noted that one should consider
the capacity of a given facility, rather than the capacity of the
sequencing platforms.
“[...] there are some practical problems like running [the sequencers]
24/7 and some working regulations. And that’s why we are [not]
operating [...]at the full capacity of the sequencers, but [rather] at
full capacity of the facility [...]”
Respondent 1
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FIGURE 1 | Organisation structure and operations of sequencing institutions. (A) Summary of respondent profiles. (B) Summary of organisation types. (C) Use
cases or purpose of human whole genome (WGS) or whole exome (WES) sequencing. In (A–C), numbers in black text at the centre of the rings represent the total,
while the numbers in white text on the rings represent the exact numbers for a particular category. (D) The various operational models practiced by the institutions
participating in the interview study, in terms of human whole genome and exome sequencing: “Dedicated”—operate sequencing platforms in-house to serve an
exclusive set of clinical and research clients. In certain cases, such institutions serve clients within a given region/locality (i.e., “Regional”). “Open”—a standard
service-oriented institution with in-house sequencing platforms. “Integrated”—institutions/departments with in-house sequencing platforms that are embedded
within a research and/or clinical unit. “Outsourced”—institutions that perform sequencing with external providers. (E) UpSet plot (Conway et al., 2017) represents the
operational models and corresponding number of sequencing institutions that utilise those models for WGS/WES. The horizontal green bars represent the total
number of a given operational model. The bottom panel represents specific combinations (or intersections) of operational models. The vertical bars represent the
number of sequencing institutions using those combinations of operational models. Detailed information available in Supplementary File 2: Table S2.
In terms of the trends and the scale of sequencing-
centered activities within the participating institutions (Figure 2),
collectively, the 33 institutions had sequenced ∼161,899 whole
genomes and ∼155,360 whole exomes (317,259 samples in
total) at the time of our interviews. The sequencing of the
first WGS began in the early 1990s (by a large consortium),
Frontiers in Genetics | www.frontiersin.org 5 May 2020 | Volume 11 | Article 303
fgene-11-00303 May 4, 2020 Time: 17:38 # 6
Narayanasamy et al. Genomic Data Access in Europe
while the first WES was generated in 2008. The sequencing
coverage (or depth) for genomes (WGS) ranged from 5× to
200× (mean = ∼51×, median = 30×) across the institutions;
for exomes (WES), the sequencing coverage ranged from 10×
to 300× (mean = ∼107×, median = 100×; Supplementary File
2: Table S4). The aggregated potential sequencing capacity of
the institutions was approximately 1.9 × 107 gigabases per year,
which translates into ∼198,000 WGS per year at 30 × coverage.
Based on this information, we additionally estimated the
potential future scale of long-term genomic data retention.
We then asked respondents to estimate the future sequencing
capacity of their institutions to help us form a clearer view on
trends in WGS/WES in EU/EEA. Respondents representing 17
different institutions indicated plans for expansion, while 15 of
them expressed a clear intention to purchase additional state-
of-the-art sequencing platforms. Figure 2 shows the estimated
combined historical and future sequencing capacity. Considering
this input, we estimated that the total future potential capacity
would increase to 3.0 × 107 gigabases per annum, equivalent to
more than 300,000 WGS at 30 × coverage. Most respondents
were unable to predict actual future sequencing capacity outside
of funded research projects (Supplementary File 2: Table S4). It
is important to note that the reported numbers and projections
are solely based on estimates provided by the respondents and
are not meant to serve as accurate measures. We note, however,
that business decisions to purchase sequencing machines may be
an indicator of perceived future demand.
Genomic Data Management
The massive output from sequencing institutions generates large
amounts of data and thus creates a downstream challenge in data
management. When specifically addressing raw genomic data
access for sequenced individuals, there were two aspects that we
were interested in: (i) what is available for access in terms of raw
genomic data file formats and (ii) how long will they remain
accessible. Those factors, however, were constrained by (i) the
capacity of the data storage infrastructure and (ii) data retention
policies, which could be dictated by either internal (institutional)
policies or national or EU regulations. Figure 3 shows the storage
duration of raw genomic data file formats and various policies
that govern retention of genomic data.
Practices
Discussions with respondents centred on the so-called raw file
formats in the genomic data processing chain, which include
(listed in order of production) the following: (i) BCL, (ii) FASTQ,
(iii) BAM (including all subtypes), and (iv) VCF. It is important
to note that those file formats may span up to 100 GB (for
WGS data), while some of those formats may be redundant (e.g.,
BAM and FASTQ). As such, VCF and FASTQ formats cannot
be converted back to the prior data format (BAM and BCL,
respectively), potentially resulting in loss of data if those prior
formats are deleted.
“That is the benefit of storing BCLs rather than FASTQs because
it’s an untouched data [. . .] when you do the demultiplexing of the
BCL, and you might [. . .]. I mean, and then you [. . .] have to make
a decision on how do you demultiplex? How do you get out the
different reads from these BCLs, and that’s a decision that, [. . .] if
you make the wrong decision, it cannot go back.”
Respondent 2
Most respondents (26, ∼79%) were committed to at least
one of the raw genomic data formats for indefinite periods
(Figure 3). Particularly, the most widely retained are FASTQ (26,
∼79%), followed by both BAM and VCF (25, ∼76%), while four
(12%) institutions committed to retaining BCL files indefinitely
(Supplementary File 2: Table S5). In most cases, sequencing
institutions maintained their own data storage (including back-
ups) and computing facilities. As such, our respondents reported
that a total of 284,522 (134,202 WGS and 150,320 WES) raw
genomic data sets were retained by the sequencing institutions,
which represented ∼90% of the total number of samples
sequenced to date (see the Actual vs. potential sequencing capacity
section and Supplementary File 2: Table S5). Respondents
explained that raw data formats were stored for future re-
analysis and re-interpretation. When specifically asked about the
sustainability of storing those files indefinitely, respondents were
generally confident in their capability to manage the data in the
near future (e.g., 5–10 years). This is further supported by the fact
that only five institutions utilise or plan to utilise state-of-the-art
genomic data compression technologies (e.g., CRAM, Hsi-Yang
Fritz et al., 2011; Bonfield, 2014) to save on data storage costs
(Supplementary File 2: Table S5). However, most respondents
considered that indefinite storage of genomic data sets might be
unsustainable long-term (e.g., >10 years).
Policies
The genomic data retention policies of sequencing institutions
ranged from 3 months to 115 years, to indefinite storage
(Figure 3). The lower end of this spectrum is typically
represented by sequencing institutions that practice the service-
oriented open operational model (see the Respondent profiles,
organisational structures, and operational models section) and
therefore enforce strict internal raw genomic data retention
(Supplementary File 2: Table S5). Consequently, the ∼10% of
those so-called “unretained” genomic data sets (Supplementary
File 2: Table S4) stem from such institutions. In contrast, seven
sequencing institutions assumed the responsibility of storing all
the genomic data in compliance with national laws for clinical
data, under the assumption that genomic data are considered
as clinical data (Supplementary File 2: Table S5). Moreover,
those sequencing institutions support clients from healthcare and
research in managing their genomic data for the time being.
“[...] we never removed anything, but [...] in our agreements
[guarantee two years of storage]. [We] are basically waiting for
healthcare to establish [...] long-term data archiving solutions. And
when those are in place, we will start moving the data there for
long-term storage, for archiving. But [any data that we have] in
our hands, we will [store] for two years. But [. . .] because our
collaborative customer [is not] ready, [we] have said [it is] too much
[of] value to destroy it [...] now, so, we keep it and if [it is] not that
expensive to store on tape [. . .], we can [absorb] the cost.”
Respondent 2
Frontiers in Genetics | www.frontiersin.org 6 May 2020 | Volume 11 | Article 303
fgene-11-00303 May 4, 2020 Time: 17:38 # 7
Narayanasamy et al. Genomic Data Access in Europe
FIGURE 2 | Actual vs. potential sequencing capacity. (A) Number of whole exomes (WES) and whole genomes (WGS) sequenced per year. (B) Total number of WES
and WGS sequenced to date. In (A,B), the number of respondents that were able to estimate the number of WES and WGS sequenced individuals are indicated in
grey text within the bars. (C) Annual predicted (70%) potential vs. actual sequencing capacity. Detailed information available in Supplementary File 2: Tables S3,
S4.
FIGURE 3 | Data retention practices and policies. Green scale represents storage practices in terms of stored file formats. Grey scale represents national and
internal institutional data storage policies reported by the respondents. Detailed information available in Supplementary File 2: Table S5.
Thirteen respondents stated that their data retention policies
are stated within their informed consent forms (Supplementary
File 2: Table S5). Upon comparing the responses to the informed
consent forms that we collected, we found that all (nine) of the
informed consent forms broadly addressed data retention, with
four clearly stating the duration of data retention.
Respondents were asked about the impact of the GDPR that
had recently come into force in May 2018. The majority of
respondents answered that necessary measures in relation to
genomic data management had been in place even before the
introduction of the GDPR, mostly due to existing stringent laws
when dealing with personal genetic information, which includes
genomic data. Only one respondent reported a change in data
management strategy because of the GDPR specifically, which
involved switching from the long-term storage of BCL files to
FASTQ to comply with the “right to be forgotten” outlined by
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GDPR. Compliance with this principle, our respondent said, was
not feasible using BCL files.
“[...] one of the changes [we are] doing is; [switching] from BCL to
FASTQs storage, because [it is easier] to remove the individuals, if
they would request that.”
Respondent 2
In summary, sequencing institutions established various
measures/strategies to manage raw genomic data, in compliance
with laws and regulations. The wide variation in data retention
policies and practices (Figure 3) is surprising considering that
most sequencing institutions face relatively similar technical
challenges, organisational priorities, and presumably also
relatively similar regulatory frameworks with regard to data
retention and data protection.
Raw Genomic Data Access for
Sequenced Individuals
In the final part of the interview, we asked the respondents if
they had ever experienced cases of individuals seeking to access
their raw genomic data. Accordingly, we documented at least 28
such cases (in 12 sequencing institutions within 10 countries)
of sequenced individuals requesting and subsequently receiving
access to their own genomic data (Figure 4). It is important to
note that all sequencing institutions that received such requests
ultimately granted access to the raw genomic data. We further
asked those respondents who managed such cases to elaborate on
how the process was carried out. We also asked all respondents
about policies governing the personal raw genomic data access.
Practices
The most common raw file format provided to the individuals
was VCF followed by BAM and FASTQ files (Supplementary
File 2: Table S6). Two respondents mentioned that the sequenced
individuals in question wanted their data to perform their own
analyses. None of the other respondents knew the exact reasons
why individuals had requested access to their own raw genomic
data, but broadly speculated that those individuals were looking
for second opinions.
“Well, it was actually a patient who wanted a second opinion
on the data. And it was an individual, who [was] educated [in]
bioinformatics, and wanted to have a look at the data [themselves]
and have some second opinion about it [...]”
Respondent 3
Sequenced individuals and sequencing institutions are not in
direct contact; therefore, access requests are relayed through an
“intermediary contact,” usually a healthcare professional, trial
master, or principal investigator (Table 1). Additionally, the
authorisation to grant access to a given sequenced individual
appears to rest solely in the discretion of the aforementioned
intermediary contact or, in some cases, is evaluated by a panel
that may involve personnel from the sequencing institution, e.g.,
respondents themselves (Table 1). The sequencing institution
(i.e., where the data resides) complies with the decision
of the intermediary contact or panel and acts accordingly
(Figure 4). In summary, those intermediary contacts may be
viewed as gatekeepers for sequenced individuals to access their
raw genomic data.
Requests were typically handled by institutions on a case-
by-case basis, using ad hoc procedures. Only one institution
confirmed a standardised internal procedure/process to comply
with such requests. Most respondents reported handing out the
data to the sequenced individual on an external hard drive,
while a small number were able to provide it via download.
Organisations employed measures such as pseudonymisation and
encryption to ensure confidentiality and security.
Four cases of personal raw genomic data access requests
occurred in sequencing institutions that were public
organisations with dedicated and/or integrated sequencing
platforms (Figure 4 and section Respondent profiles,
organisational structures, and operational models). The two
commercial sequencing institutions (with open operational
models) did not experience such requests. Furthermore,
access cases within 10 institutions were linked to clinical
utility (Figure 4), further highlighting the role of healthcare
professionals within those cases (Table 1).
Policies
We compared the reported practices of the institutions by asking
all respondents about their data access policies for sequenced
individuals, including examples of their informed consent forms.
We found that two out of nine informed consent forms provided
to us included information about individual access policies. We
also asked respondents if data access was granted based on a
certain law or policy. In general, respondents viewed data access
as a right of the individual. One respondent highlighted an
organisational policy of not providing data access to minors until
they are of legal age.
“In my own projects, we have an outspoken policy that says, they are
children and we are not giving up the data to them. So, when they
[turn] 18, and if they ask for the data, we will ask them instead, to
give a DNA sample so we will do resequencing [. . .] for them. But
we are not going to give the data to them.”
Respondent 4
Several respondents also pointed out possible contradictions
between GDPR and national laws, such as the one illustrated in
the next quote:
“[. . .] the challenge that we have is that; there is actually, at
some point, a contradiction between GDPR and [a national law
pertaining to genetic testing]. Because, for example, we are not
allowed to give genetic data [or] genetic results to the patients
without [involving a] specialist, discussing the data with the patient
first. So, when the patients request their data, we have to make sure
that we [. . . just can’t. . .] give them the data and [say], ‘so here’s all
the variants’. Even worse, if it’s a child, we cannot just give the data
to the parents [and] say, okay, we’ll do whatever you want. So that is
one [challenge], and we haven’t had a case yet that somebody asked
for that data according to GDPR, but this is an ongoing discussion
internally [on] what’s the best way [. . .].”
Respondent 5
We also observed opposing opinions on who should
bear the cost(s) associated with providing personal access
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FIGURE 4 | Generalised illustration of access in practice. (A) Typical scenario of personal whole genome (WGS) or whole exome (WES) sequencing data access.
Individuals request their data through a healthcare professional or a principal investigator. Those parties authorise the access to the genomic data. In certain cases, a
panel of experts, which may include personnel from a sequencing institution, jointly decide and authorise the access. The final decision is relayed to the sequencing
institution, which initiates the data transfer process, mediated by a healthcare professional or principal investigator. Sequenced individuals do not directly interact
with the sequencing institution. For detailed descriptions, refer to Table 1. (B) UpSet plot (Conway et al., 2017) represents the number and types of sequencing
institutions that successfully enabled personal access to raw genomic data of patients and/or research participants. The horizontal bars represent the elements of
organisational structure, purpose of sequencing, and operational model (Figure 1). The bottom panel represents the intersections between the aforementioned
elements. The vertical bars represent the size of those intersections. Detailed information available in Supplementary File 2: Tables S2, S6.
to raw genomic data, e.g., infrastructure, hardware,
and staff/administration. Specifically, one respondent
noted that the institution will not be able to cover
potential costs.
I can only say [that] the institute will not be able to pay [for the hard
drives to store the raw genomic data]. [Especially], when [...] people
are coming [to us], requesting for the data, [but] the download speed
is not fast enough, via internet. [Therefore] it is, of course, [should]
not [be] the responsibility of the institution to pay [for] it.”
Respondent 6
Another respondent highlighted that it was possible
for their institution to fund the associated cost(s),
despite the law allowing them to reject requests if costs
were too high.
“If they want to access [to the data in] electronic format, [then]
they [also have] the right to get [it] in [the] electronic format. [In
a national law] there’s also a caveat that says, if the effort and the
financial cost would be too high, then you can refuse the request.
But we see that it’s possible [. . .].”
Respondent 1
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TABLE 1 | Communication, decision, authorisation, and data transfer related to personal access to genomic data.
Communication
“[...]. In both cases, the request came via the collaborator, [because] the individuals don’t
know us. And they are not even aware that we are the ones processing their sample. [...]”
Respondent 2
“[...]. Two other cases came through the actual hospital where the patients were on treatment because
they came with a metastatic condition. The primary case or prior cases have been investigated
with us. [. . .] the patients have been asking through the hospital, where they could get access
to their data to make the most use of the old data together with the new ones out there.”
Respondent 1
“Well, [...] I don’t have any direct [contact] with the individuals. It is done by the [researchers] or by healthcare.”
Respondent 2
“Yes, it’s a medical doctor, who will send us a query and he will manage all the things
with this patient and [. . .], we are not allowed to send the data directly to people.”
Respondent 7
Decision and authorisation
“[...] the [trial] coordinator; that’s usually the first point of contact, and then
they contact for the reply of clinical heads of this program, and they decide it.”
Respondent 1
“Well, you know, since we do the service [for] other [researchers], these questions are the responsibility of
the researcher and not us, except for those projects that are [for] my research groups – internal projects.”
Respondent 4
“So, it’s discussed in committees that are set up, and then it’s kind of communicated directly to the person-owner of
the data.” Respondent 1
“[...] we came to the agreement that,[. . .] this was obviously a person who was very interested and who
had some prior knowledge of what [he asked for]. So, we decided on giving out both [the BAM and VCF].”
Respondent 3
Data transfer
“[. . .] we just need to put them on to some external hard drive or whatever, and we hand this out.”
Respondent 1
We send the data on hard drives to the collaborator, and then they send it further to
[the sequenced individuals], and we don’t know the name of individuals. We use numbers.
Respondent 8
“[...]. Right now, we had like two or three times, and we sent hard drives with the data.”
Respondent 9
Finally, it is unclear if such data access is fully compliant
with the right of individuals to access their health record or
their personal data.
Outlook
At the end of the interviews, we asked all the respondents
to provide their future outlook on such cases of personal raw
genomic data access. It must be noted that answers include both
institutional policies and personal views of respondents, whereby
the latter does not represent institutional policies. Twenty-one
(∼64%) responses were supportive of the right and providing
an option for individuals wanting to obtain access to their own
sequencing data. Fourteen (∼42%) believed that the number
of personal raw genomic data access requests from sequenced
individuals will grow in the foreseeable future. Finally, 10
(∼30%) respondents indicated that their respective organisations
were currently developing processes to manage those requests
(Supplementary File 2: Table S6).
DISCUSSION
This study represents the first empirical study of genomic data
management and personal access to raw genomic data for
sequenced individuals. It demonstrates the frequency of access
requests, the overwhelming tendency of sequencing institutions
to grant such access, as well as technical and procedural
complexities involved.
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Organisational Structure and Operational
Models
This study covered a diverse set of sequencing institutions within
the EU/EEA genomics ecosystem, with varying organisational
structures and operational models, thus providing a good
representation of the current landscape, especially in the context
of evolving regulations (i.e., GDPR).
Accountability for Data Retention and Personal
Access
The institution or department responsible for genomic data
management are typically physically, if not legally, separate
from the institution or department responsible for interaction
with sequenced individuals. However, certain organisations had
units performing both data management and communicating
with sequenced individuals within the same physical location,
but were in fact independent, yet highly collaborative entities
(e.g., departments, units, or groups). On the other end of the
spectrum were institutions within which these two functions
were located in clearly distinct institutions, with a clear service-
based relationship and minimal collaboration. Particularly for
institutions where several functions are fulfilled by the same
units, it is necessary to clarify how these functions correspond
with roles and responsibilities that are of legal relevance. The
GDPR, for example, distinguishes between “data controllers,”
who determine the purpose of processing and who are
primarily responsible for respecting individual rights, and “data
processors,” who carry out data processing services on behalf
of controllers. The GDPR also recognises the possibility of
joint controllership, where more than one party is responsible
for protecting data and meeting demands from the individual
right of access.
In light of these complex organisational structures, we
recommend that there should be clear instructions for individuals
regarding how to request access to their raw genomic data,
including a clear point of contact, when they consent to
having their genome sequenced. If requests for an individual’s
raw genomic data access are made directly to the sequencing
institution/unit, they may need to be directed back to the
appropriate access point. It should also be clear which
organisation is responsible for determining if access should be
provided, and according to what criteria. A failure to respond to
access requests under the GDPR could lead to legal liability for
both the requesting party and the sequencing institution.
Clinical Versus Research Data
One important consideration in discussion about both data
retention and right to access to raw genomic data is the
distinction between research and clinical data. Most notably,
research data may not be considered of sufficiently high quality
to enable meaningful consumer reuse (Shevchenko and Bale,
2016). Consumers may insist, however, that it is them, and
not the sequencing institution, who should be able to make
this determination, if necessary under the guidance of relevant
experts (e.g., genetic counselors). In Europe, however, the right
of data subjects to access their own raw genomic data in the
research context may be restricted by member states, under
Article 89 of the GDPR. While access rights are typical in the
clinical setting, it remains unclear whether or not raw genomic
data are considered part of patients’ medical records (Thorogood
et al., 2018). Even if there is no legal requirement, research
projects may still opt for ethical or engagement reasons to provide
access. Complicating things further is that a significant number
of sequencing institutions provide both types of sequencing
(research and clinical). The emergence of numerous national
clinical genomics projects designed as learning health systems
that routinely collect clinical data for the purposes of both care
and research is also eroding this distinction (Stark et al., 2018;
Price and Cohen, 2019).
Sequencing institutions may need processes to distinguish
between research and clinical data for the purposes of retention or
personal access. Alternatively, they may decide to adopt a single
policy on personal access for all data in favor of the strictest
requirements (i.e., to provide access).
Actual and Potential Sequencing
Capacity
Our respondents reported rapid increases in WES/WGS potential
and actual sequencing capacity from previous years. Moreover,
growing competition between manufacturers in producing the
most cost-efficient sequencing technology platforms was seen
by our respondents as providing sequencing institutions with
ample choices for further expansion of their sequencing capacity,
and thus leading them to “stock up” on sequencing capacity. It
must be noted that the unused sequencing capacity is typically
due to various limiting factors such as (i) research funding, (ii)
capacity of facility/institution, (iii) consortia activity, and (iv)
clinical demand. The latter is especially true as respondents could
not predict future actual capacity related to clinical genomic
data, likely because of (i) unclear public healthcare allocation
(budget) for WES/WES, (ii) emerging state-of-the-art sequencing
platforms, which may result in (iii) falling costs of WES/WGS.
Yet, sequencing institutions foresee performing more WES in the
near future as it currently is and it will be considerably cheaper
compared to WGS, indicating that the lowering costs of WGS is
still insufficient to justify its cost for all use cases, though it will be
important in certain niches (e.g., rare diseases).
The increasing amounts of genomic data produced in
the clinical and in the research domain will have important
ramifications for both data retention and the provision of
raw genomic data access to sequenced individuals. WES/WGS
is a platform technology, which generates rich and stable
information that can be used for multiple clinical, research,
and recreational purposes over time. Reuse of sequences has
potential value not only for sequenced individuals, but also
for healthcare systems, science, and commerce. Of course,
reuse of data depends on deployment of standard sequencing
platforms, analysis pipelines (where applicable), and file formats
to ensure both interoperability and quality. Our results suggest
significant variation in sequencing practices and pipelines. High
interoperability and quality standards are needed to ensure
that sequenced individuals can access raw genomic data for
consumer use or for redistribution to other service providers
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and researchers (patient-centric data sharing; Kish and Topol,
2015). This is to ensure that data are meaningful and trustworthy
for a number of downstream, distributed users. The right of
consumer portability (closely related to the “right to access”) has
been recognised by GDPR by stating that data controllers should
provide personal data “in a structured, commonly used, machine-
readable and interoperable format” (Recital 68). While there does
already appear to be a relatively high level of standardisation
and reproducibility for human WGS/WES data generation and
processing to enable medical and research reuse (DePristo et al.,
2011; Auwera et al., 2013), most sequencing institutions do
not currently provide levels of standardisation aiming to enable
meaningful consumer reuse. This may change with the growing
frequency and awareness of personal access to raw genomic data.
Genomic Data Management
With the rapid increase in sequencing capacity, questions arise as
to who will store raw genomic data, in what form, and for how
long. Our study, the first of its kind to review data retention,
reveals uncertainty over who was responsible for storing data.
In some cases, sequencing institutions were storing data as
a stop-gap measure until requesting organisations developed
sufficient capacity to do so. There was also a general lack of
clear institutional policies about the duration of data retention,
and significant variation between the policies that do exist
(from a couple of months to indefinite). Unclear and varied
retention policies are surprising considering legal requirements
of data retention that may apply, particularly in clinical contexts.
Retention policies were also not consistently described in the
consent forms we reviewed. This is in line with the findings of
previous reviews (Shabani et al., 2018). On the basis of these
findings, we recommend that sequenced individuals should be
provided transparent information about the length and location
of storage at the time of consenting to their DNA being
sequenced. A further area for exploration would be to determine
if these requirements apply, or should apply, to raw genomic data.
Data retention practices present important challenges. On
the one hand, longer-term storage of data can provide practical
opportunities for quality control, re-interpretation, and reuse
for secondary research purposes, and also allows individuals a
greater span of time to request personal genome access. On the
other hand, given the potential increase in sequencing capacity,
storage may soon start to pose a bottleneck and sustainability
challenge (especially as we move to WGS), though respondents
did not suggest this was an immediate problem. In the view
of advancements in sequencing technologies and the decreasing
costs of sequencing, long-term storage of data may not seem
cost-efficient. Moreover, data privacy principles such as data
minimisation, which dictates that personal data should only
be kept as long as necessary to carry out a specific purpose,
could pose challenges to long-term storage of genomic data.
The implementation of such principles into practice is still an
ongoing process among many sequencing institutions, as also
highlighted in our study. Finding ways to ensure compliance with
emerging regulatory requirements without giving up the benefits
of long-term genomic data retention is one of the key challenges
currently facing sequencing institutions in the EU/EEA (Wagner
et al., 2014). Sequencing institutions could be supported in
balancing these interests through the development of standard
storage technologies (e.g., compressed file formats, electronic
health records) and practices. This could be pursued initially
through voluntary standards organisations (e.g., Global Alliance
for Genomics and Health, GA4GH; Health Level Seven, HL7)
and through professional guidelines and best practices (e.g.,
American College of Medical Genetics and Genomics, ACMG;
Advancing Human Genetics & Genomics, ASHG; The European
Society of Human Genetics, ESHG), and could eventually be
incorporated into laboratory regulations (Botkin et al., 2015;
Deignan et al., 2019).
That said, in determining the period for data retention in the
context of raw genomic data, other existing relevant regulations,
such as those concerning minimum/maximum length for storage
of medical information in the healthcare setting may apply.
Consequently, it would be important to clarify the status of raw
genomic data, namely, whether they would be considered as part
of patient medical records or not.
Requests to Access Personal Genomic
Data
Previous work has found that individuals are typically interested
in obtaining access to their own genomic/genetic data (Lunshof
et al., 2014; Middleton et al., 2015). It may help that various
national regulations and the GDPR require data controllers
to inform data subjects of their right to access data [Article
13(2)(b)]. Moreover, as more third-party service providers
emerge, rising consumer awareness may lead to more individuals
requesting access.
At present, however, the overall number of requests for
genomic data is very modest in comparison to the number of
sequenced individuals. Possible reasons for this are the relatively
recent adoption of WES/WGS, as well as low interest, awareness,
and consumer utility. Moreover, many genomic data sets in
the EU/EEA are currently generated in research contexts that
anonymise data, thus precluding return. The plausibility of this
explanation is supported by our finding that only two access
requests were related to research genomic data. Moreover, the
complex structures and operations of sequencing institutions
may lead to a lack of clear coordination of responsibility
within and between organisations. For instance, service-oriented
commercial sequencing institutions did not see any access cases
possibly due to the lack or limited communication between
such sequencing institutions and the intermediary contact (i.e.,
clients), beyond data generation and processing. Finally, most
of the informed consent forms we analysed do not consistently
mention access rights, as addressed by previous work on this
topic (Shabani et al., 2018).
Our study found that in all cases where access was requested,
the sequencing institution gave them access, despite a lack
of formal internal policies and procedures. This is a general
indication that sequencing institutions recognise their ethical
responsibility and the rights (legal) of sequenced individuals
to access their raw genomic data. It is therefore important
for sequencing institutions to establish clear policies and
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procedures for personal raw genomic data access. As such,
one noteworthy finding of this study is the observation that
most sequencing institutions make decisions to grant access
on an ad hoc, case-by-case basis. It is unclear who within
the institution authorises the access and according to what
criteria. Similarly, there are no standards or best-practice
guidelines for protecting the privacy, security, and well-being
of sequenced individuals during the access process. Provision
of access through an intermediary with appropriate genetics
expertise can help sequenced individuals better understand the
meaning and limits of genetic data. It appears that the interaction
between research and healthcare personnel is quite common
in sequencing units integrated within healthcare institutions.
Staff of dedicated and/or integrated sequencing institutions (e.g.,
respondents) are able to communicate directly with respective
intermediary contacts, which are, in turn, able to communicate
with the patient, thus creating a conducive environment for
providing raw genomic data access to sequenced individuals.
However, present ad hoc and case-by-case-based practices may
not be scalable.
Once institutional policy about when to provide personal
genome access has been formulated, there are additional
technical and practical questions about how data will be
accessed. Technically, should data be provided on a hard
disk, through a web portal, or through the cloud? Who must
bear the cost for such access, the individual, the requesting
institution, the sequencing institution, or the healthcare system?
Security and privacy measures are also important elements that
need to be adequately protected when retaining, sharing, and
accessing sensitive data.
It should be noted that, as of yet, there is no evidence
available on what individuals do, or intend to do, with their
raw genomic data after access, and it is a matter of an
ongoing debate how much support they should receive in
understanding/interpretation of such data, and from whom.
Seeking a second opinion might be one reason for patients
to request access to their raw genomic data. Currently,
there are some third-party online services that also offer
interpretation services to the individuals (Guerrini et al., 2019).
They may also opt to share their data with interested third
parties such as biotech or pharma companies in exchange for
monetary or non-financial incentives (Ahmed and Shabani,
2019). However, it is not clear if patients should receive
professional support when using such online services. This
will, of course, depend on the context—is the interpretation
for healthcare purposes (e.g., serious disease predispositions),
or for more general preventative, well-being or recreational
purposes? If individuals are seeking medical interpretation, the
best option for individuals would be to reuse their raw genomic
data within third-party healthcare institutions, which includes
the guidance of qualified professionals by design (Wright
et al., 2017; Middleton, 2018). However, to the best of our
knowledge, this particular use case of interoperability between
EU/EEA healthcare institutions is yet to be explored and may
be highly complex given varying infrastructure, resources, and
capabilities of different healthcare institutions. Most importantly,
the aforementioned uncertainties of third-party reuse of raw
genomic data should first be explored through empirical
research to distinguish the concrete needs and risks from
hypothetical ones (Middleton, 2018). This should further guide
the development of interoperability channels specific to the reuse
of genomic data.
Limitations
A general limitation to this study is that we may not have
covered all possible types of sequencing institutions (e.g.,
commercial institutions and consortia) and personal access
requests, including those that were possibly overlooked, did
not respond, or declined to participate. Furthermore, we
did not cover ordering institutions (clients) that may have
received access requests that were not passed on to the
sequencing institutions in the study, but rather handled by
the clients themselves. Most importantly, given the complexity
of organisational relationships and structures, we were unable
to directly interview the organisation or the gatekeepers of
access requests, including healthcare professionals and expert
panels. Neither did we interview those persons within an
organisation most knowledgeable about its infrastructure (e.g.,
IT specialist) and policies (e.g., lawyer or data steward) as
this was not a criterion for the selection of interviewees (we
spoke to whoever from the organisation that agreed to speak
with us).
We would also like to highlight potential bias between
respondent sequencing institutions and those declining to be
interviewed. It may be that institutions within our professional
networks were more likely to agree to interview. Decliners can be
characterised as follows: most of the negative responses stemmed
from people who did not respond to our communication at all
or failed to schedule an interview, while five outright declined to
interview, with four of them providing reasons for rejecting (see
Supplementary File 5). If given, the most common reason for
rejection was due to the preference in answering the questions
in a written format. However, we decided against it (i.e., written
questionnaires) to maintain consistency of our data collection
methodology and also due to the nature of the open-ended
questions, which are more suited within an interview setting.
However, given that we successfully surveyed a large proportion
of identified institutions (63 of 83), it is likely that we achieved
saturation and so this bias is expected to be limited.
We also did not systematically analyse differences in
national regulatory frameworks, written institutional policies,
and governance documents (if they exist), outside the limited
number of informed consent forms. In that regard, we were
unable to compare information from statements within the
interviews with a complete set of informed consent forms
from the organisations, outside the limited number of informed
consent forms obtained from those organisations, used for
validation. It is also crucial to investigate other potential
professional concerns from the perspectives of the healthcare
professionals that may disfavor personal access to raw genomic
data. Future research may also want to consider cross-
country comparisons of sequencing institution structure, data
retention, and personal access. Our exploratory study aimed at
identifying general trends rather than making these granular
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comparisons. Moreover, our central finding, that few institutions
have formally addressed retention or personal access, seems to
have general implications across Europe. Our study remains
the first exploratory study providing empirical evidence on the
organisational structures, current and future sequencing capacity,
and approaches to genomic data retention and personal genome
access of sequencing institutions located in the EU/EEA.
Outlook
We find that sequencing capacity in Europe is growing and that
some sequenced individuals are requesting access to their raw
genomic data. Despite these trends, we also find that sequencing
institutions are largely unprepared to handle questions of
retention and personal access, and have yet to develop clear
policies and practices. In a broader context, this study gives
insight into the complexity and the general direction of the
emerging genomics ecosystem. In that regard, we hope that this
study becomes a catalyst for future explorations of similar nature
with other stakeholders of the genomics ecosystem, and enhances
the development policies and best practices in the context of
personal access to raw genomic data.
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